Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?

Area of Science:

• Nephrology
• Cardiology
• Geriatrics

Background:

• Cardiovascular disease (CVD) is a leading cause of mortality in chronic kidney disease (CKD) patients.
• Factors contributing to CVD in CKD include advanced age, hypertension, uremic toxins, and inflammation.
• Sarcopenia, characterized by decreased muscle strength, is increasingly recognized in CKD and linked to adverse outcomes.

Purpose of the Study:

• To review the current literature on the relationship between sarcopenia and cardiovascular disease (CVD) in patients with chronic kidney disease (CKD).
• To explore the contributing factors to CVD in advanced CKD stages.
• To understand the impact of sarcopenia on CVD risk and mortality.

Main Methods:

• Literature review of recent studies.
• Analysis of factors contributing to CVD in CKD.
• Examination of the association between sarcopenia and CVD outcomes.

Main Results:

• High incidence of CVD and mortality in CKD patients.
• Sarcopenia is prevalent in CKD and associated with increased physical disability, reduced quality of life, and mortality.
• Emerging evidence indicates sarcopenia independently increases CVD risk and mortality.

Conclusions:

• Sarcopenia is a significant risk factor for cardiovascular disease and mortality in both CKD and non-CKD populations.
• Interventions such as exercise and nutritional supplementation may mitigate sarcopenia progression.
• Further research is warranted to elucidate the mechanisms linking sarcopenia and CVD in CKD.